NASDAQ:CTXR - Citius Pharmaceuticals Stock Price, Forecast & News

Citius Pharmaceuticals trades on the NASDAQ under the ticker symbol "CTXR."

Citius Pharmaceuticals shares reverse split before market open on Friday, June 9th 2017. The 1-15 reverse split was announced on Thursday, June 8th 2017. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, June 8th 2017. An investor that had 100 shares of Citius Pharmaceuticals stock prior to the reverse split would have 7 shares after the split.

2 Wall Street analysts have issued 1-year target prices for Citius Pharmaceuticals' stock. Their forecasts range from $3.00 to $7.00. On average, they expect Citius Pharmaceuticals' share price to reach $5.00 in the next year. This suggests a possible upside of 879.6% from the stock's current price. View Analyst Price Targets for Citius Pharmaceuticals.

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Citius Pharmaceuticals in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Citius Pharmaceuticals.

News headlines about CTXR stock have trended extremely negative recently, according to InfoTrie Sentiment. The research group identifies negative and positive media coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Citius Pharmaceuticals earned a media sentiment score of -5.0 on InfoTrie's scale. They also gave headlines about the company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an impact on the stock's share price in the near future. View News Stories for Citius Pharmaceuticals.

Citius Pharmaceuticals saw a decrease in short interest during the month of November. As of November 29th, there was short interest totalling 250,300 shares, a decrease of 6.3% from the November 14th total of 267,100 shares. Based on an average daily trading volume, of 168,300 shares, the days-to-cover ratio is presently 1.5 days. Approximately 1.6% of the company's shares are sold short. View Citius Pharmaceuticals' Current Options Chain.

Some companies that are related to Citius Pharmaceuticals include Aridis Pharmaceuticals (ARDS), Humanigen (HGEN), Vascular Biogenics (VBLT), Alimera Sciences (ALIM), Zomedica Pharmaceuticals Corp (NYSEAMERICAN) (ZOM), PLx Pharma (PLXP), Evoke Pharma (EVOK), Forward Pharma A/S (FWP), Acer Therapeutics (ACER), Celsion (CLSN), DiaMedica Therapeutics (DMAC), Edesa Biotech (EDSA), Sunesis Pharmaceuticals (SNSS), Teligent (TLGT) and Seelos Therapeutics (SEEL).

Based on aggregate information from My MarketBeat watchlists, some companies that other Citius Pharmaceuticals investors own include Progenics Pharmaceuticals (PGNX), Real Goods Solar (RGSE), SCYNEXIS (SCYX), Opko Health (OPK), Canopy Growth (CGC), Flex Pharma (FLKS), Idera Pharmaceuticals (IDRA), Melinta Therapeutics (MLNT), SenesTech (SNES) and Zynerba Pharmaceuticals (ZYNE).

Citius Pharmaceuticals' stock is owned by many different of institutional and retail investors. Top institutional investors include Sabby Management LLC (3.83%). Company insiders that own Citius Pharmaceuticals stock include Leonard L Mazur and Myron Z Holubiak. View Institutional Ownership Trends for Citius Pharmaceuticals.

CTXR stock was purchased by a variety of institutional investors in the last quarter, including Sabby Management LLC. Company insiders that have bought Citius Pharmaceuticals stock in the last two years include Leonard L Mazur and Myron Z Holubiak. View Insider Buying and Selling for Citius Pharmaceuticals.

Shares of CTXR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of CTXR stock can currently be purchased for approximately $0.51.

Citius Pharmaceuticals has a market capitalization of $11.27 million. The company earns $-12,530,000.00 in net income (profit) each year or ($1.17) on an earnings per share basis. Citius Pharmaceuticals employs 7 workers across the globe.View Additional Information About Citius Pharmaceuticals.

The official website for Citius Pharmaceuticals is http://www.citiuspharma.com/.

Citius Pharmaceuticals' mailing address is 11 Commerce Drive First Floor, Cranford NJ, 07016. The company can be reached via phone at 908-967-6677.